Globus Medical (GMED)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Globus Medical.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 78.80 $ — 59% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 42.2% passed
- More than 10% revenue growth is expected for the coming year 6.3% failed
- Share count grows by less than 3% a year 10.2% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 36.7% failed
- Gross margin at 40% or higher and without meaningful erosion 67.4% passed
- Goodwill from acquisitions does not grow faster than revenue 27.1% failed
- Net debt below twice EBITDA 439 m net cash passed
- Operating cash flow covers the profits of the last three years 754 m passed
- Return on capital at 15% or higher, or up versus two years ago 10.0% passed
- Insiders hold at least 10% or are net buyers 0.7% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 31.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 14
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4.74 | 4.70 – 4.78 | 3,202 | 19.1% | 15 |
| 12/31/2027 | 5.15 | 4.93 – 5.30 | 3,403 | 8.5% | 15 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 1.12 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.19 | 75.40 | 657 | 6.60 | 4.00 | 210 | 193 |
| 2025: Q1 | 0.54 | – | 598 | -1.40 | 12.60 | 177 | 136 |
| 2025: Q2 | 1.49 | 540.90 | 745 | 18.40 | 27.20 | 78 | 26 |
| 2025: Q3 | 0.88 | 134.00 | 769 | 22.90 | 15.50 | 250 | 219 |
| 2025: Q4 | 1.02 | 440.20 | 826 | 25.70 | 17.00 | 249 | 192 |
| 2026: Q1 | 0.90 | 66.60 | 760 | 27.00 | 16.40 | 202 | 163 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 564 | 154 | 104 | 1.08 | 172 | 832 | 928 |
| 2017 | 636 | 162 | 107 | 1.10 | 160 | 968 | 1,079 |
| 2018 | 713 | 169 | 156 | 1.54 | 182 | 1,186 | 1,301 |
| 2019 | 785 | 172 | 155 | 1.52 | 172 | 1,402 | 1,532 |
| 2020 | 789 | 111 | 102 | 1.01 | 199 | 1,506 | 1,679 |
| 2021 | 958 | 172 | 149 | 1.44 | 276 | 1,741 | 1,957 |
| 2022 | 1,023 | 228 | 190 | 1.85 | 178 | 1,846 | 2,076 |
| 2023 | 1,568 | 133 | 123 | 1.07 | 244 | 3,998 | 5,086 |
| 2024 | 2,519 | 166 | 103 | 0.75 | 521 | 4,177 | 5,252 |
| 2025 | 2,939 | 480 | 538 | 3.92 | 753 | 4,573 | 5,303 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Globus Medical, Inc. entwickelt und kommerzialisiert Gesundheitslösungen für Patienten mit muskuloskelettalen Erkrankungen in den USA und international.
| Employees | 6,000 |
|---|---|
| Headquarters | Audubon, PA |
| Address | 2560 General Armistead Avenue, 19403-5214 Audubon, United States |
| Phone | 610 930 1800 |
| Website | globusmedical.com |
| IPO Date | 3. Aug 2012 |
| ISIN | US3795772082 |
Management
| Name | Title | Birth Year |
|---|---|---|
| David C. Paul | Co-Founder & Executive Chairman | 1967 |
| Keith W. Pfeil | CEO, President & Director | 1979 |
| Kyle R. Klin | Senior VP & CFO | 1986 |
| Kelly G. Huller Esq. | Executive VP, General Counsel & Corporate Secretary | 1972 |
| Brian J. Kearns | Senior Vice President of Business Development & Investor Relations | 1967 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Davidar David D | Director | Other | 2,500 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.